自身抗体预测类风湿关节炎进展:系统综述与荟萃分析
该系统综述与荟萃分析纳入26项合格研究,评估自身抗体阳性个体进展为类风湿关节炎的相对风险与累积发病率。自身抗体阳性者发生RA的风险增加3.1至19.3倍,其中CCP2阳性合并关节痛及IgM-RF者12个月累积发病率最高达35.2%(95%CI 29.3%至41.2%)。
要点
- 自身抗体阳性个体发生RA的风险较阴性者增加3.1至19.3倍。
- CCP2阳性合并关节痛及IgM-RF者12个月累积发病率最高为35.2%。
- 关节痛个体进展风险随时间变化,随访前24个月风险最高。
核心结论
- CCP2与IgM-RF联合关节痛者进展为RA速度最快。
- 关节痛个体进展风险随时间变化,前24个月风险最高。
研究设计与样本
- 系统文献检索于2025年8月进行,293篇全文通过筛选,26篇纳入荟萃分析。
- 回顾性病例对照研究用于计算RA相对风险,前瞻性观察研究或随机对照试验用合并生存模型估计累积发病率。
主要发现
- 血清自身抗体阳性使发生RA风险增加3.1至19.3倍。
- CCP2阳性合并关节痛及IgM-RF者12个月累积RA发病率为35.2%(95%CI 29.3%至41.2%)。
- 前瞻性研究按关节痛、IgM-RF存在与否及一/二级亲属RA史分组分析CCP2或CCP3阳性个体。
关键数值与推荐
- CCP2阳性合并关节痛及IgM-RF者12个月累积RA发病率为35.2%(95%CI 29.3%至41.2%)。
- 自身抗体阳性个体发生RA的相对风险范围为3.1至19.3倍。
临床怎么用
- 对CCP2阳性合并关节痛及IgM-RF者应密切监测,尤其在前24个月。
- 自身抗体阳性个体需根据抗体类型及关节痛等附加因素分层评估RA进展风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of this systematic review and meta-analysis was to examine autoantibody positive individuals and define: (a) the relative risk of rheumatoid arthritis (RA) compared with autoantibody negative individuals and (b) the cumulative incidence of RA over time, in different populations. METHODS: A systematic literature search was performed in August 2025. Retrospective case control studies of individuals with RA and healthy matched controls were identified and relative risk of RA was calculated. Prospective observational studies or randomised controlled trials of autoantibody positive individuals were identified and pooled survival models were used to estimate cumulative incidence of progression to arthritis. RESULTS: 293 full-text articles fulfilled screening criteria and 26 were eligible for meta-analysis. The presence of serum autoantibodies confers between a 3.1--19.3-fold increase risk of developing RA. Prospective studies of anticyclic citrullinated peptide 2 (CCP2) or CCP3 positive individuals were grouped according to additional criteria; presence of arthralgia, presence/absence of immunoglobulin M rheumatoid factor (IgM-RF) and first-degree or second-degree relatives with RA. The estimated cumulative incidence of RA at 12 months was highest for CCP2 positive individuals with arthralgia and IgM-RF, at 35.2% (95% CI 29.3% to 41.2%). CONCLUSION: A considerable number of autoantibodies have been examined as predictors for RA; however, the fastest rate of progression to RA in this study occurred in those with CCP2 and IgM-RF in combination with arthralgia. Importantly, the risk of developing RA changes over time for individuals with arthralgia, and they are at the highest risk of progression within the first 24 months of follow-up. PROSPERO REGISTRATION NUMBER: CRD42021231245.
引用
- Qureshi S, Adas M, Cope PJ, et al. Autoantibodies as predictors of progression to rheumatoid arthritis: a systematic review and meta-analysis. RMD Open. 2026. PMID: 41672721. doi:10.1136/rmdopen-2025-006368
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。